Redefining Prevention and Management of Portal Hypertension Complications

Nov 08 2026
Convention Center: Mile High Ballroom 2B-3B
8:00 AM - 9:30 AM
Captured/recorded session Recorded
CE Credits CE Credits

World Class Speakers

Sunil Dadhich

Abstract Presenter
Sunil Dadhich, MBBS, MD, DM

K Rajender Reddy

Abstract Presenter
K Rajender Reddy, MD, FAASLD

Mohammad Alabbas

Abstract Presenter
Mohammad Alabbas, M.D

Jonggi Choi

Abstract Presenter
Jonggi Choi

Sagnik Biswas

Abstract Presenter
Sagnik Biswas, DM

Naim Alkhouri

Abstract Presenter
Naim Alkhouri

Jacqueline G O'Leary

Moderator
Jacqueline G O'Leary, MD, MPH

Stevan A. Gonzalez

Moderator
Stevan A. Gonzalez, MD

Description

The treatment landscape for portal hypertension complications continues to expand beyond traditional therapies. Advances in pharmacologic management, refinements in TIPS technology, and novel approaches to ascites, encephalopathy, and decompensation prevention are reshaping patient care. This session will present cutting-edge clinical trials evaluating established and emerging therapies and examine how disease-modifying interventions may alter the natural history of cirrhosis.

Presentations

8:00 AM - 8:15 AM
Convention Center - Mile High Ballroom 2B-3B
Recorded session

Safety and Efficacy of SGLT-2 Inhibitors in Liver Cirrhosis Patients with Refractory Ascites: A Randomised Clinical Control Trial

Sunil Dadhich, MBBS, MD, DM | Abstract Presenter
8:15 AM - 8:30 AM
Convention Center - Mile High Ballroom 2B-3B
Recorded session

Early Results of a Prospective Multicenter Trial of the Liverty™ TIPS Stent Graft with Tailored Expansion for Portal Hypertension Complications

K Rajender Reddy, MD, FAASLD | Abstract Presenter
8:30 AM - 8:45 AM
Convention Center - Mile High Ballroom 2B-3B
Recorded session

High-Intensity Statin Continuation After First Hepatic Decompensation in MASLD Cirrhosis: A Propensity-Matched Signal Challenging Low-Dose Paradigms

Mohammad Alabbas, M.D | Abstract Presenter
8:45 AM - 9:00 AM
Convention Center - Mile High Ballroom 2B-3B
Recorded session

Association Between Direct Oral Anticoagulant Initiation and Hepatic Decompensation in Compensated Cirrhosis and Atrial Fibrillation: A Propensity Score-Matched Landmark Cohort Study

Jonggi Choi | Abstract Presenter
9:00 AM - 9:15 AM
Convention Center - Mile High Ballroom 2B-3B
Recorded session

A multicenter, randomized controlled trial comparing endoscopic ultrasound-guided coil and glue embolization with balloon-occluded retrograde transvenous obliteration for prevention of rebleeding from gastric varices

Sagnik Biswas, DM | Abstract Presenter
9:15 AM - 9:30 AM
Convention Center - Mile High Ballroom 2B-3B
Recorded session

ANTICIPATE-NASH Risk Stratification Predicts Variceal Development in Compensated MASH Cirrhosis: Results from the NAVIGATE Trial

Naim Alkhouri | Abstract Presenter

Objectives

  • Evaluate emerging pharmacologic therapies, including SGLT-2 inhibitors, statins, and direct oral anticoagulants, for preventing decompensation and improving outcomes in patients with cirrhosis
  • Assess advances in procedural management of portal hypertension complications, including next-generation TIPS technologies and novel approaches to preventing gastric variceal rebleeding
  • Interpret contemporary risk prediction models, including ANTICIPATE-NASH, to identify patients at highest risk for variceal development and portal hypertension progression

Copyright © 2026 American Association for the Study of Liver Diseases

AASLD 2026